We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
- Authors
Turner, Benjamin; Cree, Bruce A. C.; Kappos, Ludwig; Montalban, Xavier; Papeix, Caroline; Wolinsky, Jerry S.; Buffels, Regine; Fiore, Damian; Garren, Hideki; Han, Jian; Hauser, Stephen L.
- Abstract
Objective: The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I (NCT01247324) and OPERA II (NCT01412333) phase III studies has been reported; here we present subgroup analyses of efficacy endpoints from the pooled OPERA I and OPERA II populations. Methods: Patients with RMS were randomized to either ocrelizumab 600 mg administered by intravenous infusion every 24 weeks or subcutaneous IFN β-1a 44 µg three times per week throughout the 96-week treatment period. Relapse, disability, and MRI outcomes were analyzed for predefined and post hoc subgroups based on demographic and disease characteristics along with prior treatment using appropriate statistical tests to determine the treatment effect in subgroups and treatment-by-subgroup interactions. Results: The significant treatment benefit of ocrelizumab, versus IFN β-1a, observed in the overall OPERA I and OPERA II pooled populations was maintained across most subgroup strata for all endpoints, including annualized relapse rate, disability progression, and MRI outputs. Conclusions: The treatment effect of ocrelizumab versus IFN β-1a, measured by clinical and MRI outcomes, was maintained across most of the subgroups and strata of interest, and the pattern of treatment benefit across all subgroups was consistent with that from the pooled OPERA studies.
- Subjects
MULTIPLE sclerosis; MULTIPLE sclerosis treatment; INTRAVENOUS therapy; DEMOGRAPHIC characteristics
- Publication
Journal of Neurology, 2019, Vol 266, Issue 5, p1182
- ISSN
0340-5354
- Publication type
Article
- DOI
10.1007/s00415-019-09248-6